Ankylosing Spondylitis Pipeline Drugs

(Albany, US) DelveInsight launched its new report on Ankylosing Spondylitis Pipeline Insights, 2020.

Ankylosing Spondylitis Pipeline Insight, 2020” report by DelveInsight outlays comprehensive insights of present clinical development scenario and growth prospects across the Ankylosing Spondylitis market. A detailed picture of the Ankylosing Spondylitis pipeline landscape is provided, which includes the disease overview and Ankylosing Spondylitis treatment guidelines.

The assessment part of the report embraces in-depth Ankylosing Spondylitis commercial assessment and clinical assessment of the Ankylosing Spondylitis pipeline products from the pre-clinical developmental phase to the marketed phase. In the report, a detailed description of the drug is proffered including mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Ankylosing Spondylitis collaborations, licensing, mergers and acquisition, funding, designations, and other product-related details.

Key pharma players involved in Ankylosing spondylitis market are:

  1. UCB Inc.
  2. AbbVie
  3. Pfizer
  4. Amgen/Pfizer
  5. Janssen Biotech
  6. Pozen
  7. Novartis
  8. Merck
  9. Horizon Pharma
  10. Iroko Pharmaceuticals
  11. And Many More

Request for free Sample Report: https://www.delveinsight.com/sample-request/ankylosing-spondylitis-bekhterevs-disease-pipeline-insight

Key benefits of the report:

  • In the coming years, Ankylosing Spondylitis market is set to change due to the rising awareness of the disease, and incremental healthcare spending across the world; which would expand the size of the market to enable the drug manufacturers to penetrate more into the market
  • The companies and academics are working to assess challenges and seek opportunities that could influence Ankylosing Spondylitis R&D. The therapies under development are focused on novel approaches to treat/improve the disease condition
  • Major players are involved in developing therapies for Ankylosing Spondylitis. Launch of emerging therapies will significantly impact the Ankylosing Spondylitis market
  • A better understanding of disease pathogenesis will also contribute to the development of novel therapeutics for Ankylosing Spondylitis
  • Our in-depth analysis of the pipeline assets across different stages of development (Phase III and Phase II), different emerging trends and comparative analysis of pipeline products with detailed clinical profiles, key cross-competition, launch date along with product development activities will support the clients in the decision-making process regarding their therapeutic portfolio by identifying the overall scenario of the research and development activities

“The United States accounts for the highest prevalent population of Ankylosing Spondylitis, followed by EU5 and Japan.”

Request for free Sample Report: https://www.delveinsight.com/sample-request/ankylosing-spondylitis-bekhterevs-disease-pipeline-insight

Drugs involved are:

  1. Cimzia
  2. Humira
  3. Celebrex
  4. Enbrel
  5. Simponi
  6. Vimovo
  7. Cosentyx
  8. Arcoxia
  9. Rayos
  10. Indocin
  11. And Many More

Ankylosing spondylitis (AS), also called as Bechterev’s disease is a form of arthritis that primarily affects the spine, although other joints may also be involved. It causes inflammation of the spinal joints (vertebrae) that can lead to severe, chronic pain and discomfort. It is a type of axial spondyloarthritis (axSpA) that refers to a particular form of spondyloarthritis in which the predominant symptom is inflammatory back pain.

Ankylosing spondylitis has no known specific cause, though genetic factors seem to be involved. In particular, people who have HLA-B27 gene are at increased risk of developing ankylosing spondylitis.

On the basis of severity, AS is classified as mild or early AS (stable AS) and severe or advanced AS (active). Early AS usually starts with dull pain in the lower back and the back stiffness, whereas severe AS is associated with continuous inflammation that leads to scarring and permanent damage.

Request for free Sample Report: https://www.delveinsight.com/sample-request/ankylosing-spondylitis-bekhterevs-disease-pipeline-insight

Table of contents:

  1. Report Introduction
  2. Ankylosing Spondylitis
  3. Ankylosing Spondylitis Current Treatment Patterns
  4. Ankylosing Spondylitis – DelveInsight’s Analytical Perspective
  5. Therapeutic Assessment
  6. Ankylosing Spondylitis Late Stage Products (Phase-III)
  7. Ankylosing Spondylitis Mid Stage Products (Phase-II)
  8. Early Stage Products (Phase-I)
  9. Pre-clinical Products and Discovery Stage Products
  10. Inactive Products
  11. Dormant Products
  12. Ankylosing Spondylitis Discontinued Products
  13. Ankylosing Spondylitis Product Profiles
  14. Ankylosing Spondylitis Key Companies
  15. Ankylosing Spondylitis Key Products
  16. Dormant and Discontinued Products
  17. Ankylosing Spondylitis Unmet Needs
  18. Ankylosing Spondylitis Future Perspectives
  19. Ankylosing Spondylitis Analyst Review
  20. Appendix
  21. Report Methodology

21.1. Secondary Research

21.2. Expert Panel Validation

Related reports:

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Ankit Nigam
Email: [email protected]
Phone: +19193216187
City: Albany
State: New York
Country: United States
Website: https://www.delveinsight.com/

By sthakur